Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Issue 9 (1st March 2017)

• Record Type: Journal Article
• Authors: Webber, Chris; Patton, Michael; Patterson, Scott; Schmoele-Thoma, Beate; Huijts, Susanne M.; Bonten, Marc J.M.
• Is Part Of: Vaccine. Volume 35:Issue 9(2017)
• Page Start: 1266
• Page End: 1272
• Publication Date: 2017-03-01
• Subjects: Community-acquired pneumonia -- Invasive pneumococcal disease -- PCV13 -- Pneumococcal conjugate vaccine -- Vaccine efficacy -- Adult; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2017.01.032
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: The 23 remaining exploratory endpoints of CAPiTA are reported. PCV13 efficacy was 28.9–75.0% and was significant for 8 exploratory endpoints. Significant efficacy included all confirmed pneumococcal CAP and IPD episodes. VT serotype 1 and 7F was most common among PCV13 and placebo vaccinees, respectively. Findings support primary CAPiTA analysis showing PCV13 prevented VT-CAP and VT-IPD. Abstract: Background: The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) assessed vaccine-type community-acquired pneumonia (VT-CAP) and vaccine-type invasive pneumococcal disease (VT-IPD) prevention with 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾65 years. We report vaccine efficacy (VE) of PCV13 for the remaining 23 exploratory endpoints and serotype distributions for pneumococcal CAP and IPD. Methods: This was a parallel-group, randomised, placebo-controlled, double-blind trial comparing single-dose PCV13 with placebo. Exploratory CAP endpoints included first episode of confirmed non-VT (NVT) pneumococcal CAP; all confirmed episodes of NVT pneumococcal CAP, pneumococcal CAP, nonbacteraemic/noninvasive (NB/NI) VT pneumococcal CAP, and NB/NI pneumococcal CAP; and first and all episodes of culture-confirmed VT pneumococcal CAP, culture-confirmed pneumococcal CAP, culture-confirmed NVT pneumococcal CAP, probable VT pneumococcal CAP, probable NVT pneumococcal CAP, and probable and possible pneumococcal CAP. Exploratory IPD endpoints included all episodes of VT-IPD and IPD, and first and all episodes of NVT-IPD. The per-protocol and modified intent-to-treat (mITT) populations were evaluated. Results: In total, 84, 496 participants were enrolled. Eight of 23 exploratory CAP and IPD endpoints were statistically significant in both populations. In the per-protocol population, these included VE of 29% for all episodes of confirmed pneumococcal CAP, 43% for all NB/NI episodes of VT pneumococcal CAP, 52% for all episodes of culture-confirmed pneumococcal CAP, and 53% for all episodes of IPD. Comparable VE estimates were observed in the mITT population. The most common VT serotypes were 1 (10 first episodes of confirmed pneumococcal CAP; 2 first episodes of IPD) and 7F (22; 7) among PCV13 and placebo recipients, respectively. Conclusions: The results of this analysis yielded statistically significant PCV13 VE for all episodes of confirmed pneumococcal CAP (including NB/NI and culture-confirmed episodes) and for all episodes of IPD in adults aged ⩾65 years. These findings are consistent with the primary efficacy analysis. ClinicalTrials.gov identifier:NCT00744263 .